Morning Breakouts

Latest KFF Health News Stories

Separated Immigrant Teenagers Being Forced To Take Psychotropic Drugs Without Consent, Court Documents Show

Morning Briefing

In one case, the facility staff told a teenager that she wouldn’t be released until she was deemed psychologically sound as a way to get her to take the drugs. Under most states’ laws, before a child is medicated, a parent, guardian, or authority acting in the place of the parent must be consulted and give informed consent. But in these shelters, the children are alone.

As Democrats Campaign For A House Takeover, Health Care Becomes Wedge Issue Dividing The Party

Morning Briefing

On the more progressive side of the party, there’s a push for a “Medicare For All” type plan, while on the more moderate end, there’s a focus on fixing and shoring up the health law. The mixed messaging could muddy the waters in the coming high-tension midterms. Meanwhile, Republicans are trying to get ahead of criticism over rising premiums.

Democrats Press Senate Republicans To Go On Record Supporting Pre-Existing Coverage Protections

Morning Briefing

The effort is led in a large part by vulnerable Democrats up for reelection. “This is a test of the Republican Party, whether or not they’re going to do the right thing when it comes to protecting people with pre-existing conditions,” said Sen. Bob Casey (D-Pa.). In other health law news: lawmakers want answers over cuts to outreach groups; Republican measures block D.C. from adding an individual mandate requirement; Americans say they find it harder to afford health care this year; and more.

Merck Is Latest Drugmaker To Lower Some Prices, Earning Political Points As White House Prepares Cost Plan

Morning Briefing

Merck follows Pfizer and Novartis in dropping prices on a few of their drugs. But, like with the other two, beneath the promise is a strategy that makes it uncertain if consumers will benefit. For example, Merck lowered the cost of its hepatitis C drug, Zepatier. But that treatment has not gained traction in the U.S. marketplace anyway, so the drop could actually be an attempt to boost Merck sales for an underperforming drug.